Blood Based Biomarkers Market Size & Growth Forecast 2026–2035, By Segments (End Use, Type, Application, Technology), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Blood Based Biomarkers Market size was worth USD 8.24 Billion in 2025 and is expected to grow at a 7.3% CAGR between 2026 and 2035, reaching USD 16.67 Billion by 2035. The industry revenue for 2026 is assessed at USD 8.77 billion.
Get more details on this report
Request Free Sample ReportBlood Based Biomarkers Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 45.35% share, driven by advanced clinical testing infrastructure, precision medicine adoption, and strong integration of biomarker diagnostics across oncology, neurology, and cardiovascular care.
- Asia Pacific expands at 8.25% CAGR, supported by rising diagnostic demand, expanding healthcare access, and growing adoption of scalable blood-based testing across large patient populations.
Segment Momentum
- Hospitals & Clinics held a 49.72% share in 2025 because biomarker testing is integrated into routine diagnosis, disease monitoring, and physician-led treatment planning, supported by high patient volumes and established care pathways.
- Diagnostic laboratories are expanding rapidly as demand grows for specialized testing, efficient sample processing, broader test menus, and scalable workflows that support increasing biomarker-based screening and monitoring requirements.
Market Expansion Drivers
- Rising prevalence of cardiovascular and chronic diseases increasing demand for early diagnostic biomarkers.
- Advancements in NGS and liquid biopsy technologies improving non-invasive disease detection accuracy.
- Expanding pharmaceutical investment in precision medicine accelerating biomarker-driven therapeutic development.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Major companies in the blood based biomarkers market include Abbott Laboratories (United States), F. Hoffmann-La Roche AG (Switzerland), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (United States), bioMérieux SA (France), Bio-Rad Laboratories Inc. (United States), Sysmex Corporation (Japan), Danaher Corporation (United States), QuidelOrtho Corporation (United States), Illumina Inc. (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As cardiovascular disorders, cancer, diabetes, and other long-duration conditions become more common, clinical practice is shifting toward earlier risk stratification and routine monitoring, driving demand for the blood based biomarkers market. Physicians and health systems increasingly rely on blood-based indicators to detect disease before severe symptoms emerge, prioritize high-risk patients, and guide follow-up testing without immediately resorting to more invasive or expensive procedures. This pattern strengthens market development by expanding biomarker use from specialized oncology settings into broader chronic disease management, where repeat testing, longitudinal monitoring, and preventive care pathways create sustained purchasing and adoption.
Advancements in NGS and liquid biopsy technologies improving non-invasive disease detection accuracy
Improvements in sequencing sensitivity, assay design, and circulating biomarker analysis are making non-invasive testing more clinically actionable, supporting market expansion for the blood based biomarkers market. Better detection of low-abundance signals in blood increases physician confidence in using these tools for screening support, treatment selection, and disease monitoring, particularly when tissue access is limited or serial assessment is needed. As NGS and liquid biopsy platforms become more standardized and analytically robust, laboratories and healthcare providers are more willing to integrate blood-based biomarker panels into routine workflows, increasing market penetration through wider clinical acceptance rather than experimental use alone.
Expanding pharmaceutical investment in precision medicine accelerating biomarker-driven therapeutic development
Pharmaceutical companies are embedding biomarker strategies into drug discovery, trial design, and companion diagnostic planning, which is reinforcing market demand for the blood based biomarkers market. In practice, this investment increases the need for validated blood-based markers that can identify responsive patient subgroups, track treatment response, and support faster clinical decision-making during development programs. As precision medicine pipelines grow, biomarker developers, diagnostic firms, and drug manufacturers form tighter commercial and research partnerships, driving market development by linking blood-based testing directly to therapeutic commercialization and patient selection strategies.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of cardiovascular and chronic diseases increasing demand for early diagnostic biomarkers | 2.00% | High | North America, Europe | High | Near Term |
| Advancements in NGS and liquid biopsy technologies improving non-invasive disease detection accuracy | 1.80% | High | North America, Asia Pacific | High | Mid Term |
| Expanding pharmaceutical investment in precision medicine accelerating biomarker-driven therapeutic development | 1.50% | Moderate | Europe, North America | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 45.35% share of the blood based biomarkers market in 2025, bolstered by its established clinical testing infrastructure, broad integration of biomarker-driven diagnostics into care pathways, and strong presence of companies engaged in assay development and commercialization. The region’s leadership is aided by higher adoption of precision medicine approaches across oncology, neurology, and cardiovascular care, where blood-based testing fits practical clinical needs by enabling earlier detection, monitoring, and treatment selection through routine laboratory workflows.
Asia Pacific is projected to expand at an 8.25% CAGR over the forecast period, with growth in the blood based biomarkers market being fueled by rising diagnostic demand, expanding healthcare access, and increasing use of advanced testing across large patient populations. Momentum in the region is also tied to the gradual strengthening of hospital laboratory capabilities and greater uptake of biomarker-based screening and disease management tools, particularly where blood-based methods offer a more scalable and accessible option than more invasive diagnostic procedures.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Translational Diagnostics FocusGermany advances blood based biomarkers through translational research and clinical laboratory integration. The market emphasizes standardized validation processes, reliable diagnostic performance, and adoption within healthcare systems seeking earlier disease identification and personalized treatment decisions.
France 🇫🇷
Preventive Care ApplicationsFrance encourages the adoption of blood based biomarkers to strengthen preventive healthcare and disease monitoring. Research organizations and healthcare providers focus on clinically relevant biomarkers that support earlier diagnosis and improved treatment planning in routine medical practice.
Italy 🇮🇹
Clinical Laboratory AdoptionItaly expands blood based biomarker utilization through hospital laboratories and diagnostic service providers seeking improved clinical decision-making. Market priorities include validated testing workflows, practical implementation, and collaboration between research institutions and healthcare networks.
Japan 🇯🇵
Precision Diagnostic IntegrationJapan focuses on incorporating blood based biomarkers into precision diagnostics for oncology, neurology, and chronic disease management. Healthcare providers prioritize clinically validated biomarkers that improve routine testing efficiency while supporting individualized patient care strategies.
South Korea 🇰🇷
Molecular Testing ExpansionSouth Korea strengthens the blood based biomarkers market through investments in molecular diagnostics and advanced laboratory capabilities. Clinical institutions emphasize rapid assay development, data-driven diagnostics, and integration with precision healthcare programs across multiple therapeutic areas.
United States 🇺🇸
Clinical Innovation PipelineThe U.S. blood based biomarkers market is driven by strong clinical research, precision medicine initiatives, and expanding diagnostic applications. Healthcare organizations prioritize biomarker validation, integration with advanced laboratory platforms, and collaboration between biotechnology developers and healthcare providers.
Segment Leadership and Growth Trends
Blood Based Biomarkers Market Share (%), End Use, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportHospitals & Clinics held the leading position in the blood based biomarkers market in 2025, accounting for a 49.72% share. Their dominance is sustained by their central role in patient diagnosis and treatment workflows, where biomarker testing is closely tied to routine clinical evaluation, disease monitoring, and physician-led decision-making. The blood based biomarkers market continues to rely heavily on these settings because they offer direct access to patient volumes, integrated care pathways, and immediate test utilization in therapeutic planning.
Diagnostic Laboratories represent the fastest-growing segment in the blood based biomarkers market as demand increases for more specialized and scalable testing environments. Their momentum is being underpinned by the growing need for efficient sample processing, broader test menus, and dedicated diagnostic capabilities that can handle rising biomarker-based screening and monitoring requirements. Compared with traditional point-of-care clinical settings, diagnostic laboratories are gaining ground because they are better positioned to absorb expanding testing volumes and support increasingly structured biomarker assessment workflows.
Type Segment Analysis: Genetic Biomarkers (Largest Segment) vs Cell-Based Biomarkers (Fastest-Growing Segment)
Genetic Biomarkers led the blood based biomarkers market in 2025 with a 35.98% share. This segment maintains its leadership because genetic analysis remains foundational in identifying disease-associated variations, supporting risk assessment, and informing clinical interpretation across a wide range of applications. In the blood based biomarkers market, genetic biomarkers benefit from established clinical relevance and consistent integration into testing approaches where molecular-level insights are essential for diagnosis and patient stratification.
Cell-Based Biomarkers are the fastest-growing segment in the blood based biomarkers market, influenced by rising interest in capturing more dynamic biological information from blood samples. Their growth is underpinned by the need for biomarker approaches that reflect real-time disease activity and treatment response more directly than static molecular indicators alone. Relative to alternative biomarker types, cell-based biomarkers are gaining traction because they align well with evolving diagnostic requirements that increasingly emphasize functional and patient-specific disease monitoring.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End Use | Hospitals & Clinics, Diagnostic Laboratories, Research & Academic Institutes, Others | Hospitals & Clinics | Diagnostic Laboratories |
| Type | Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers | Genetic Biomarkers | Cell-Based Biomarkers |
| Application | Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Others | Cancer | Neurological Diseases |
| Technology | Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Others | Next-Generation Sequencing | Polymerase Chain Reaction |
Competitive Landscape and Market Positioning
1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche AG (Switzerland)
3. Siemens Healthineers AG (Germany)
4. Thermo Fisher Scientific Inc. (United States)
5. bioMérieux SA (France)
6. Bio-Rad Laboratories Inc. (United States)
7. Sysmex Corporation (Japan)
8. Danaher Corporation (United States)
9. QuidelOrtho Corporation (United States)
10. Illumina Inc. (United States)
Advancements in precision medicine and non-invasive diagnostics are accelerating activity within the blood based biomarkers market. Developers are integrating AI-enabled analytics and molecular testing platforms to improve disease detection accuracy and personalized treatment planning. Continuous research into novel biomarker identification and liquid biopsy technologies is also strengthening clinical adoption across oncology, neurology, and chronic disease management applications.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Labcorp | Aug-25 | Labcorp successfully launched the first FDA-cleared blood test for Alzheimer’s disease in the United States. This regulatory milestone provides a critical pathway for more accessible, early-stage diagnostics, facilitating broader clinical adoption of biomarker-driven care models and enhancing decision-making processes for patients and healthcare providers across the country. |
| Quanterix Corporation | Jan-25 | Quanterix Corporation entered a definitive merger agreement to acquire Akoya Biosciences. This integration combines specialized capabilities in ultra-sensitive detection for blood- and tissue-based protein biomarkers. The strategic move is designed to accelerate biomarker translation workflows, consolidate market positioning in proteomics, and realize operational cost synergies while expanding the combined entity's customer footprint. |
| Alzheimer's Drug Discovery Foundation | Mar-26 | The Alzheimer's Drug Discovery Foundation launched a $50 million Diagnostics Accelerator initiative focused on advancing blood-based biomarkers. By targeting tau-related blood tests and AI-enabled diagnostic platforms, the program aims to bridge the gap between emerging biomarker research and clinical implementation, supporting precision medicine initiatives and accelerating the commercialization of non-invasive neurodegenerative disease detection tools. |
| Circular Genomics | Dec-25 | Circular Genomics secured $15 million in Series A funding to expedite the clinical validation and commercialization of its circular RNA-based biomarker platform. The investment provides the necessary capital to scale its proprietary diagnostic technology and strengthen its competitive standing in the development of next-generation, high-accuracy blood-based screening solutions for early Alzheimer’s disease detection. |
| Biogen Inc. | Jul-24 | Biogen Inc., in collaboration with Beckman Coulter and Fujirebio, established a strategic partnership to develop minimally invasive, blood-based biomarkers specific to tau pathology in Alzheimer’s disease. This alliance focuses on creating novel diagnostic tools capable of stratifying patients and monitoring therapeutic responses, addressing a critical need for standardized, scalable diagnostics in the neurodegenerative treatment pipeline. |
| Cleveland Diagnostics, Inc. | Jan-24 | Cleveland Diagnostics raised over $75 million in growth capital, led by Novo Holdings, to accelerate the development of its non-invasive, blood-based diagnostic portfolio. The funding supports the expansion of the company’s platform, including the IsoPSA prostate cancer test, aimed at improving diagnostic accuracy, reducing rates of clinical overdiagnosis, and streamlining early-detection workflows in oncology. |
| Metabolic | May-26 | Metabolic has integrated Roche’s plasma p-Tau217 blood test into its healthcare service offerings to target early Alzheimer’s detection in high-risk patient populations. This initiative marks a significant advancement in routine clinical screening, utilizing high-sensitivity diagnostic assays to transition from specialized research settings into broader, metabolically-focused patient care pathways for neurodegenerative disease monitoring. |
| Quest Diagnostics | Oct-25 | Quest Diagnostics validated that two of its proprietary blood-based biomarker tests for Alzheimer’s disease meet stringent clinical guideline-based accuracy thresholds. This technical confirmation enhances clinical confidence in blood-based diagnostic pathways, supporting the transition toward non-invasive testing protocols as a standard of care for confirming Alzheimer’s pathology in routine clinical and primary care settings. |
| Neurophet | May-26 | Neurophet is expanding its operational reach through new pharmaceutical collaborations and multiple U.S. hospital pilot projects focused on Alzheimer’s disease. The company is actively positioning its AI-driven neuroimaging and biomarker solutions for commercial scale-up, addressing the growing demand for integrated diagnostic support tools that facilitate early detection and clinical management of neurodegenerative conditions. |
| FYR | Apr-25 | FYR has initiated a collaboration with the Mayo Clinic to leverage an extracellular vesicle-based AI platform for identifying novel blood-based biomarkers associated with Parkinson’s disease. This research-focused partnership aims to enhance the discovery and development of advanced diagnostic tools, ultimately improving early identification capabilities and enabling more effective therapeutic monitoring for complex neurodegenerative disorders. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Blood Based Biomarkers Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Blood Based Biomarkers Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the blood based biomarkers market?
What are the growth projections for the blood based biomarkers industry?
How is rising chronic disease prevalence influencing adoption of blood-based biomarkers in early diagnosis?
How are NGS and liquid biopsy advancements reshaping clinical adoption of blood-based biomarkers?
Why do hospitals and clinics lead the blood based biomarkers market?
Why are diagnostic laboratories the fastest-growing end-use segment in the blood based biomarkers market?
Why does North America dominate the blood based biomarkers market?
How is Asia Pacific driving growth in blood based biomarkers?
Who are the leading players in the blood based biomarkers landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization